HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$2.0b

HUTCHMED (China) Past Earnings Performance

Past criteria checks 5/6

HUTCHMED (China) has been growing earnings at an average annual rate of 66.8%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 16.3% per year. HUTCHMED (China)'s return on equity is 36.6%, and it has net margins of 83.3%.

Key information

66.83%

Earnings growth rate

67.41%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate16.32%
Return on equity36.58%
Net Margin83.30%
Next Earnings Update30 Jul 2026

Recent past performance updates

Recent updates

Seeking Alpha • Jan 30

Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)

Summary Despite a 32% drop in share price, HCM's oncology treatments show potential for growth, with expected revenue increases driving earnings and share price up. HCM's sale of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million will fund internal product development, enhancing its market position. The current share price of $13.56 suggests an attractive valuation with a FWD P/E of 18.1 and an EV/Sales of 2.44. However, concerns over poor performance of the share prices of Li family-controlled companies led us to downgrade HCM from Buy to Hold. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Hutchmed Growing Sales By 64% In H1 2024

Summary Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan. Read the full article on Seeking Alpha
Seeking Alpha • Mar 20

Hutchmed Is Turning Profitable

Summary Hutchmed China is a biopharmaceutical company with a market capitalization of $3 billion. HCM's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. The company delivered a profit of $100.8 million in 2023 and has a strong cash position of over $880 million. FDA approval at the end of last year, and hopefully similar approvals from the EU and Japan will be a gamechanger for HCM. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Hutchmed (China) (NASDAQ:HCM) said it began dosing in a phase 2/3 trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. Warm autoimmune hemolytic anemia is an autoimmune disorder characterized by premature destruction of healthy red blood cells (hemolysis). The main goal of the phase 2 stage is evaluating the safety and preliminary efficacy of sovleplenib and main goal is the proportion of patients with overall hemoglobin (Hb) response by week 24. If results are positive, phase 3 stage will be started wherein the main goal would be the proportion of patients who achieve a durable Hb response by week 24, the company said in an Oct. 10 press release. The company expects to enroll 110 patients. Hutchmed noted that it currently retains all rights to sovleplenib worldwide. The drug is also being studied in immune thrombocytopenia, indolent non-Hodgkin's lymphoma and multiple subtypes of B-cell malignancies in China, U.S. and Europe.

Revenue & Expenses Breakdown

How HUTCHMED (China) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:HCM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 255494571030
30 Sep 25575462100-12
30 Jun 2560246797-23
31 Mar 25616252105-12
31 Dec 24630381130
30 Sep 24621-2118-25
30 Jun 24611-42123-49
31 Mar 2472429128-25
31 Dec 238381011330
30 Sep 237983612972
30 Jun 23757-29125145
31 Mar 23592-19513072
31 Dec 22426-3611360
30 Sep 22414-3081440
30 Jun 22401-2551520
31 Mar 22376-2351440
31 Dec 21356-1951270
30 Sep 21317-1871080
30 Jun 21279-178890
31 Mar 21258-151720
31 Dec 20228-126610
30 Sep 20221-117550
30 Jun 20209-110540
31 Mar 20204-102510
31 Dec 19205-106530
30 Sep 19205-93550
30 Jun 19214-87510
31 Mar 19214-83510
31 Dec 18214-75490
30 Sep 18218-72460
30 Jun 18217-61460
31 Mar 18230-39440
31 Dec 17241-27430
30 Sep 17240-7430
30 Jun 1723813420
31 Mar 1722712410
31 Dec 1621612400
30 Sep 1620038510
30 Jun 16200-8370
31 Mar 16189-22340
31 Dec 15178-35300
30 Sep 15168-80120

Quality Earnings: HCM has a large one-off gain of $478.8M impacting its last 12 months of financial results to 31st December, 2025.

Growing Profit Margin: HCM's current net profit margins (83.3%) are higher than last year (6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HCM has become profitable over the past 5 years, growing earnings by 66.8% per year.

Accelerating Growth: HCM's earnings growth over the past year (1111%) exceeds its 5-year average (66.8% per year).

Earnings vs Industry: HCM earnings growth over the past year (1111%) exceeded the Pharmaceuticals industry -4.8%.

Return on Equity

High ROE: HCM's Return on Equity (36.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/03 11:45
End of Day Share Price 2026/07/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish